These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 18942607

  • 1. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.
    Rayhanabad JA, Difronzo LA, Haigh PI, Romero L.
    Am Surg; 2008 Oct; 74(10):887-90. PubMed ID: 18942607
    [Abstract] [Full Text] [Related]

  • 2. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI.
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [Abstract] [Full Text] [Related]

  • 3. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
    Kaplan HG, Malmgren JA, Atwood M.
    Breast J; 2009 Oct; 15(5):454-60. PubMed ID: 19671105
    [Abstract] [Full Text] [Related]

  • 4. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
    Gradishar WJ, Hansen NM, Susnik B.
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY.
    Breast J; 2013 Apr; 19(3):269-75. PubMed ID: 23614365
    [Abstract] [Full Text] [Related]

  • 7. Impact of oncotype DX recurrence score in the management of breast cancer cases.
    Nguyen MT, Stessin A, Nagar H, D'Alfonso TM, Chen Z, Cigler T, Hayes MK, Shin SJ.
    Clin Breast Cancer; 2014 Jun; 14(3):182-90. PubMed ID: 24486121
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS.
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.
    Paik S.
    Oncologist; 2007 Jun; 12(6):631-5. PubMed ID: 17602054
    [Abstract] [Full Text] [Related]

  • 13. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
    Amato NA, Partipilo V, Mele F, Boscia F, De Marzo P.
    Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Understanding tumor profiling and assessing treatment.
    Hyams DM.
    Manag Care; 2008 Jul; 17(7 Suppl 7):4-8; discussion 17-8. PubMed ID: 19093336
    [Abstract] [Full Text] [Related]

  • 17. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
    Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S.
    Breast Cancer Res Treat; 2011 Apr; 126(3):797-802. PubMed ID: 21197567
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.